NCT07061080 - Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Advanced Neuroendocrine Carcinomas of The Digestive SystemAdvanced Neuroendocrine Carcinomas Unknown Primary Origin

Interventions

DRUG

Tarlatamab

Tarlatamab as a standalone treatment through intravenous infusion at 10 mg dose every 14 days (i.e. 2 weeks)

DRUG

standard of care second-line chemotherapy (FOLFIRI)

FOLFIRI:: irinotecan intravenously 180 mg/m2 on day 1, followed by 400 mg/m2 folinic acid or 200 mg/m² levofolinate in a 2-h infusion, a 10-min bolus of 400 mg/m2 5-FU, and 2400 mg/m2 5-FU over 46 hours; every 14 days).

Trial Locations (19)

15706

Hospital Clínico Universitario de Santiago, Santiago de Compostela

28007

Hospital General Universitario Gregorio Marañón, Madrid

28034

H.U Ramón y Cajal, Madrid

28041

Hospital 12 de Octubre, Madrid

28046

H.U La Paz, Madrid

29200

Brest University Hospital Centre, Brest

31300

Centre Hospitalier Universitaire de Toulouse, Toulouse

33076

Centre Régional de Lutte Contre le Cancer Institut Bergonié (Bordeaux), Bordeaux

39008

Hospital Universitario Marqués de Valdecilla, Santander

46026

Hospital Universitario y Politécnico La Fe, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

54519

Institut de Cancérologie de Lorraine (CLCC) Nancy, Vandœuvre-lès-Nancy

59020

Centre Oscar Lambret, Lille

69003

Hôpital Edouard Herriot (Hospices Civils Lyon), Lyon

94800

Gustave Roussy, Villejuif

Unknown

Institut de Cancérologie de l'Ouest (Angers/Nantes), Nantes

08916

H.U Germans Trias i Pujols, Badalona

08035

H.U. Vall d'Hebron, Barcelona

09006

Hospital Universitario de Burgos (HUBU), Burgos